Atea Pharmaceuticals, Inc. (AVIR) Wednesday revealed that its Phase 2 study of Bemnifosbuvir and Ruzasvir Regimen for the treatment of Hepatitis C Virus or HCV achieved primary endpoint of safety and sustained virologic response.
In the pre-market session, AVIR shares reached $3.67, up 0.19 points or 5.46 percent from the previous close of $3.48.
The study showed 98% sustained virologic response at 12 weeks post-preatment, after eight weeks of treatment. In the Phase 2 study, 99% of non-cirrhotic and infected with genotypes 1-4 achieved SVR12, while the treatment adherent patients with cirrhosis achieved a 88% SVR12 rate. The global Phase 2 study has enrolled 275 treatment-naïve patients, both with and without compensated cirrhosis.
The clinical-stage biopharmaceutical company further expects initiation of the global Phase 3 Program early in 2025.
Bemnifosbuvir is a nucleotide analog polymerase inhibitor, and Ruzasvir is an NS5A inhibitor.
Atea said the regimen was "generally safe and well-tolerated with no drug-related serious adverse events or treatment discontinuations."
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.